More than half of patients with tardive dyskinesia who used valbenazine experienced symptomatic remission at 48 weeks, and nearly all of them had meaningful response, according to data presented at Psych Congress Elevate in Las Vegas.
Symptom measurements began to return to baseline totals after treatment was halted, Dawn Vanderhoef, PhD, director of medical affairs, psychiatry at Neurocrine Biosciences, based in California, and colleagues wrote.
The researchers aimed to evaluate the potential of valbenazine (Ingrezza, Neurocrine Biosciences) to meaningfully reduce involuntary movement

ORLANDO — Among older U.S. adults, there has been an increase in respiratory failure and chronic kidney disease mortality rates from 1999 to 2021, according to a poster presented at the American Thoracic Society International Conference.
“People with kidney disease frequently develop significant respiratory complications,” Filza Rahat Khan, MBBS, emergency medicine registrar at Royal Blackburn Hospital, East Lancashire Hospitals NHS Trust in the U.K., told Healio. “The interaction between these two conditions is clinically important and often underappreciated.”
Using 1999 to 2024 data from the

Among adults with hereditary angioedema, navenibart lowered the rate of monthly attacks regardless of age, BMI and baseline attack rate, according to post hoc analysis findings.
These data on navenibart (BioCryst), “an investigational long-acting monoclonal antibody inhibitor of plasma kallikrein,” were presented at the 2026 European Academy of Allergy and Clinical Immunology Annual Congress.
In a post hoc analysis of the multicenter, dose-ranging, proof-of-concept, open-label phase 1b/2 ALPHA-STAR trial, Sinisa Savic, MBBS, PhD, professor of clinical immunology at the University of Leeds, and